5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 6, 2005, Pages

  Camacho, Raul C ^a,b   Lacy, D Brooks ^a   James, Freyja D ^a   Donahue, E Patrick ^a   Wasserman, David H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

5 aminoimidazole 4 carboxamide 1 D ribosyl 5 monophosphate; Adenosine 5 monophosphate; AMP activated protein kinase; Glycogenolysis; Hepatic glucose production

Indexed keywords

3 HYDROXYBUTYRIC ACID; 5 AMINOIMIDAZOLE 4 CARBOXAMIDE 1 BETA DEXTRO RIBOFURANOSIDE; 5 AMINOIMIDAZOLE 4 CARBOXAMIDE 1 BETA DEXTRO RIBOSYL 5 MONOPHOSPHATE; ACETYL COENZYME A CARBOXYLASE; ADENOSINE PHOSPHATE; CATECHOLAMINE DERIVATIVE; FATTY ACID; FURAN DERIVATIVE; GLUCAGON; GLUCOSE; GLYCEROL; HYDROCORTISONE; INSULIN; LACTIC ACID; SOMATOSTATIN; UNCLASSIFIED DRUG; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5' AMP ACTIVATED PROTEIN KINASE; 5'-AMP-ACTIVATED PROTEIN KINASE; AICA RIBONUCLEOTIDE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOGEN; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE; RIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CATHETERS AND TUBES; CONTROLLED STUDY; DOG; ENZYME PHOSPHORYLATION; FEMALE; GLUCONEOGENESIS; HYPERINSULINEMIA; INFUSION; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; ANIMAL; ARTERY; BLOOD; CHEMISTRY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; LIVER; METABOLISM; PHOSPHORYLATION;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ARTERIES; BLOOD GLUCOSE; DOGS; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLYCOGEN; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; KINETICS; LIVER; MALE; MULTIENZYME COMPLEXES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDES;

EID: 33644683699     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00247.2005     Document Type: Article

References (31)

1. Al-Khalili L, Krook A, Zierath JR, and Cartee GD. Prior serum and AICAR-induced AMPK activation in primary human myocytes does not lead to subsequent increase in insulin-stimulated glucose uptake. Am J Physiol Endocrinol Metab 287: E553-E557, 2004.
2. Beauloye C, Marsin AS, Bertrand L, Krause U, Hardie DG, Vanoverschelde JL, and Hue L. Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett 505: 348-352, 2001.
3. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR, 3rd Young LH, and Shulman GI. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50: 1076-1082, 2001.
4. Bergeron R, Russell RR III, Young LH, Ren JM, Marcucci M, Lee A, and Shulman GI. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol Endocrinol Metab 276: E938-E944, 1999.
5. Bishop JS, Goldberg ND, and Larner J. Insulin regulation of hepatic glycogen metabolism in the dog. Am J Physiol 220: 499-506, 1971.
6. Camacho RC, Pencek RR, James F, Lacy DB, and Wasserman DH. Portal venous 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside overcomes hyperinsulinemic suppression of endogenous glucose output. Diabetes 54: 373-382, 2005.
7. Camacho RC, Pencek RR, Lacy DB, James FD, and Wasserman DH. Suppression of endogenous glucose production by mild hyperinsulinemia during exercise is determined predominantly by portal venous insulin. Diabetes 53: 285-293, 2004.
8. Carling D and Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1012: 81-86, 1989.
9. Corton JM, Gillespie JG, Hawley SA, and Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229: 558-565, 1995.
10. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45: 937-948, 2002.
11. Edgerton DS, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumann WC, Landau BR, Rossetti L, and Cherrington AD. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50: 1872-1882, 2001.
12. Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, and Nuttall FQ. Integrated effects of multiple modulators on human liver glycogen phosphorylase a. Am J Physiol Endocrinol Metab 283: E29-E37, 2002.
13. Exton JH, Lewis SB, Ho RJ, Robison GA, and Park CR. The role of cyclic AMP in the interaction of glucagon and insulin in the control of liver metabolism. Ann NY Acad Sci 185: 85-100, 1971.
14. Finegood DT, Bergman RN, and Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36: 914-924, 1987.
15. Gamble J and Lopaschuk GD. Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism 46: 1270-1274, 1997.
16. Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, and Kraegen EW. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulinresistant high-fat-fed rats. Diabetes 51: 2886-2894, 2002.
17. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, and Alessi DR. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833-843, 2004.
18. Lloyd B, Burrin J, Smythe P, and Alberti KG. Enzymatic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate. Clin Chem 24: 1724-1729, 1978.
19. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, and Allard MF. 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol 284: R936-R944, 2003.
20. Mari A. Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol Endocrinol Metab 263: E400-E415, 1992.
21. McCrimmon RJ, Fan X, Ding Y, Zhu W, Jacob RJ, and Sherwin RS. Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus. Diabetes 53: 1953-1958, 2004.
22. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, and Kahn BB. AMPkinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428: 569-574, 2004.
23. Namkoong C, Kim MS, Jang PG, Han SM, Park HS, Koh EH, Lee WJ, Kim JY, Park IS, Park JY, and Lee KU. Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Diabetes 54: 63-68, 2005.
24. Parker JC and Jarett L. Insulin mediator stimulates pyruvate dehydrogenase of intact liver mitochondria. Diabetes 34: 92-97, 1985.
25. Pencek RR, Shearer J, Camacho RC, James FD, Lacy DB, Fueger PT, and Wasserman DH. 5′-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 54: 355-360, 2005.
26. Perrin C, Knauf C, and Burcelin R. Intracerebroventricular infusion of glucose, insulin and the AMP-activated kinase activator AICAR controls muscle glycogen synthesis. Endocrinology 145: 4025-4033, 2004.
27. Sakamoto K, Goransson O, Hardie DG, and Alessi DR. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 287: E310-E317, 2004.
28. Shang J and Lehrman MA. Activation of glycogen phosphorylase with 5-aminoimidazole-4-carboxamide riboside (AICAR). Assessment of glycogen as a precursor of mannosyl residues in glycoconjugates. J Biol Chem 279: 12076-12080, 2004.
29. Shearer J, Fueger PT, Vorndick B, Bracy DP, Rottman JN, Clanton JA, and Wasserman DH. AMP kinase-induced skeletal muscle glucose but not long-chain fatty acid uptake is dependent on nitric oxide. Diabetes 53: 1429-1435, 2004.
30. Witters LA and Kemp BE. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5′-AMP-activated protein kinase. J Biol Chem 267: 2864-2867, 1992.
31. Young ME, Radda GK, and Leighton B. Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR-an activator of AMP-activated protein kinase. FEBS Lett 382: 43-47, 1996.